UnitedHealth Group reported a robust start to 2019, with strong growth in revenues (up 9%), adjusted EPS (up 23%), and raised full-year earnings expectations. The company emphasized its strategic advances in pharmacy services, digital health, and healthcare delivery. The management's tone was confident, highlighting successful ongoing innovations and business expansions. While there are potential headwinds like the return of the health insurance tax, the raised 2019 earnings guidance and strong Q1 performance are likely to positively influence the stock in the short term.

[1]